Global Seizure Detection Devices Market Trends and Insights
Rising Epilepsy Prevalence and Diagnostic Undersupply
The seizure detection devices market draws demand from a large population that needs continuous monitoring outside specialist centers. The World Health Organization reports that 50 million people have epilepsy globally and that nearly 80% live in low- and middle-income countries. A 2025 meta-analysis reported a pooled global epilepsy prevalence of 7.57 per 1,000 people and found an upward trend through 2025. The 2024 Global Burden of Disease analysis documented substantial geographic variation in epilepsy burden, reinforcing the need for care models that do not rely only on specialist facilities. The market can address part of this gap by supporting longer observation in settings where access to EEG services is limited. Demand will remain linked to the capacity of health systems to identify patients and connect them with follow-up care.Growing Adoption of Wearable and Remote Monitoring
Wearable and remote monitoring is making the seizure detection devices market more accessible to patients who need continuous observation outside the hospital. Empatica received FDA clearance for EpiMonitor in June 2025, expanding use of the EmbracePlus wristband for children aged 6 years and older. A 2025 review covering 67 studies found accelerometers were the most commonly used sensor type, appearing in 61.2% of studies. These products can reduce stigma when monitoring is integrated into familiar consumer devices. They also make caregiver alerts possible in home and community settings, although the clinical value remains dependent on seizure type and alert accuracy.False-Positive and False-Negative Detection Burden
Device accuracy remains a restraint for the seizure detection devices market because missed seizures and unnecessary alerts can disrupt care. A 2026 prospective study found that a wrist-worn accelerometry device detected all 16 generalized convulsive seizures but detected none of the 510 focal seizures observed over 373 monitoring days. The study also recorded 29 false alarms, largely linked to everyday movement. A 2025 validation study found that reduced-channel wearable EEG had more false detections in ambulatory use than in a monitored unit, with all ambulatory false positives occurring in pediatric participants. These results favor multimodal and EEG-centered systems where clinical use requires detection of a wider range of seizure types. They also require providers to establish response protocols that account for alert burden.Other drivers and restraints analyzed in the detailed report include:
- AI-Enabled Detection and Multimodal Biosensing
- Wider Regulatory Clearances for Children and Nighttime Use
- Reimbursement Gaps and High Total Cost of Ownership
Segment Analysis
Wearable devices held 42.67% of product-type demand in 2026. Their use reflects demand for discreet, continuous monitoring and compatibility with familiar consumer hardware. The product category includes wrist-worn platforms that measure movement, skin conductance, or related physiological signals. EpiMonitor and NightWatch+ expanded the range of cleared wearable options during 2025. These systems are most aligned with visible motor events and nighttime caregiver alerts. Their limitation is that peripheral signals do not reliably identify focal-onset seizures.EEG-based systems are projected to advance at a 12.88% CAGR through 2032, the fastest rate among product categories. This growth stems from the need to identify focal seizures that wristbands and bed sensors can miss. The seizure detection devices market size for EEG-based systems is supported by clinical demand for electrographic evidence rather than indirect signs. Bed and movement sensors remain relevant for pediatric and residential uses where wearable adherence may be difficult. Video and audio systems can improve inpatient documentation and support seizure characterization. Implantable and subcutaneous EEG options provide longer-term recording, but procedural demands and cost limit use to a narrower clinical population.
EEG represented 38.26% of detection-technology demand in 2026. It remains the reference method for detecting electrographic activity and for evaluating focal-onset events. American Clinical Neurophysiology Society guidance supports continuous EEG monitoring for high-risk neonatal and pediatric patients, which reinforces its role in institutional care. EEG can provide evidence that peripheral sensors cannot capture. This distinction is important where a treatment decision requires confirmation of seizure activity. Reduced-channel and wearable EEG designs are making the technology more suitable for extended use outside the hospital.
Multimodal monitoring is expected to grow at a 13.24% CAGR through 2032. It combines EEG with accelerometry, ECG, electrodermal activity, photoplethysmography, or related signals. The 2025 review found activity measures in 53.7% of studies, cardiovascular measures in 49.3%, brain activity in 35.8%, and skin conductance in 34.3%. This pattern shows why no single sensor can capture the full physiological range of seizures. Accelerometry remains widely deployed because it has low power requirements and fits consumer wearables. The seizure detection devices industry is therefore moving toward signal combinations that can balance detection performance with comfort and battery life.
Complete Report Scope:
- By Product Type
- Wearable Seizure Detection Devices
- Bed and Movement Sensors
- EEG-Based Seizure Detection Systems
- Video and Audio Seizure Monitoring Systems
- Implantable and Subcutaneous EEG Monitoring Devices
- Others
- By Detection Technology
- Accelerometry
- Electrodermal Activity
- Heart Rate and Photoplethysmography
- Electroencephalography
- Electromyography
- Others
- By Seizure Type
- Generalized Tonic-Clonic Seizures
- Focal Seizures
- Hyperkinetic Seizures
- Nocturnal Seizures
- Seizure Clusters
- Others
- By End User
- Hospitals
- Neurology Clinics
- Home Care Setting
- Ambulatory and Outpatient Clinics
- Others
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 38.25% of global demand in 2026. The seizure detection devices market benefits in the region from established epilepsy monitoring centers, a steady FDA clearance pipeline, and growing attention to payer coverage. The United States has a large population requiring epilepsy care, and some patients remain poorly controlled despite treatment. EpiMonitor received clearance that broadened the patient groups eligible for monitoring in 2025. FDA Class II requirements remain a central compliance factor for manufacturers that want access to the U.S. care system. The region also provides early adoption opportunities for systems that combine point-of-care EEG with software-based clinical review.Asia-Pacific is projected to grow at a 15.39% CAGR through 2032. The seizure detection devices market size in the region is supported by unmet epilepsy needs, healthcare infrastructure investment, and expanding digital care channels. The World Health Organization notes that the majority of people with epilepsy live in low- and middle-income countries, many of which are in this region. China has a large undiagnosed population and is increasing domestic medical device activity. India is expanding telemedicine capacity, which can help providers reach patients where specialist access is constrained. Japan and South Korea have supportive conditions for wearable EEG adoption because of established health coverage and high digital health use. Empatica expanded EpiMonitor access to Australia, New Zealand, and Canada, creating a distribution footprint that includes the Pacific region. Regulatory pathways and local reimbursement decisions will determine how quickly consumer-style monitoring converts into clinical use.
Europe, the Middle East and Africa, and South America show different demand conditions within the seizure detection devices market. Europe has an established clinical base and growing interest in home video EEG as an alternative to inpatient admissions. Neuraxpharm and mjn-neuro announced plans for a 2026 European launch of EPISERAS, a CE MDR Class IIa-certified AI earpiece for people with drug-resistant epilepsy. CE MDR certification is a major compliance factor for developers seeking European access. Africa has a high epilepsy burden and faces cost, infrastructure, and specialist-care barriers. The World Health Organization's Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders is encouraging national attention to these gaps. In South America, Eurofarma and SK Biopharmaceuticals formed Mentis Care in October 2025 to develop AI-powered seizure prediction and monitoring platforms for Latin America and other markets. These regions will need business models that match local purchasing capacity and care infrastructure.
List of Companies Covered in this Report:
- Brain Sentinel Inc.
- BrainScope Company Inc.
- Cadwell
- Ceribell Inc.
- CGTec Kommunikationssysteme GmbH
- Compumedics
- DannuWave Ltd.
- Empatica Srl
- Epitel Inc.
- EpiWatch Inc.
- GE Healthcare
- Koninklijke Philips
- LivaNova
- Masimo
- Medtronic
- Natus Medical
- Neuro Event Labs Oy
- Nihon Kohden
- Seer Medical Pty Ltd
- UNEEG medical A/S
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Brain Sentinel Inc.
- BrainScope Company Inc.
- Cadwell Industries Inc.
- Ceribell Inc.
- CGTec Kommunikationssysteme GmbH
- Compumedics Limited
- DannuWave Ltd.
- Empatica Srl
- Epitel Inc.
- EpiWatch Inc.
- GE HealthCare
- Koninklijke Philips NV
- LivaNova PLC
- Masimo Corporation
- Medtronic plc
- Natus Medical Incorporated
- Neuro Event Labs Oy
- Nihon Kohden Corporation
- Seer Medical Pty Ltd
- UNEEG medical A/S

